AI
Claude Grew a Lab Coat: Anthropic's Wet Lab Moves AI Into Real Biology
The AI lab that spent September urging caution is also the one building a real biology lab. Reuters reported on September 18 that Anthropic has quietly set up a wet lab in the San Francisco Bay Area, a facility for physical experiments, as it pushes its ambitions into drug science. Eric Kauderer-Abrams, Anthropic's head of life sciences, confirmed the lab in a Reuters interview: "We believe that to do biology, the final test is still and will be for a while in real lab work."
The move takes Anthropic beyond computer simulation. The company's biology work has gone past "in silico" evaluations into physical experiments, run through a hybrid model with some work in its own facilities and some with external partners. A spokesperson clarified that the lab is designated for fundamental biology rather than drug discovery specifically, and the company is staying clear of clinical trials and direct competition with pharmaceutical and biotech firms.
The ambition behind the lab is large. Anthropic says it wants to unlock treatments for rare diseases that the pharmaceutical industry has given limited attention, a goal with personal roots: Amodei has spoken about his father dying of a disease only a few years before a cure arrived. Life sciences have become one of the company's largest investment areas by headcount and capital, backed by software like Claude Science, a roughly $400 million April acquisition of stealth biotech Coefficient Bio, and the addition of Novartis CEO Vas Narasimhan to its board. This week the company also launched a Life Sciences Verification Program giving vetted researchers access to its most powerful models.
The most striking detail is what the company wants Claude to do next. Anthropic is exploring having its models direct robotic units to carry out science experiments with limited human intervention, with human oversight kept central for safety. Kauderer-Abrams called the effort "the very early innings of using AI to automate the execution of lab work," which makes the direction of travel the real story: from models that reason about biology to models that do biology.
For readers, this is the clearest sign yet that frontier AI is moving from the screen to the bench. In the same week the industry debated slowing down, one of its leading labs showed where the acceleration is actually pointed: at diseases that have waited too long for attention, with AI running experiments that turn theories into treatments.
Quick answers
What is this story about?
The AI lab that spent September urging caution is also the one building a real biology lab. Reuters reported on September 18 that Anthropic has quietly set up a wet lab in the San Francisco Bay Area, a facility for physical experiments, as it pushes its ambitions into drug science. Eric Kauderer-Abrams, Anthropic's head of life sciences, confirmed the lab in a Reuters interview: "We believe that to do biology, the final test is still and will be for a while in real lab work."
Why does this story matter?
For readers, this is the clearest sign yet that frontier AI is moving from the screen to the bench. In the same week the industry debated slowing down, one of its leading labs showed where the acceleration is actually pointed: at diseases that have waited too long for attention, with AI running experiments that turn theories into treatments.
Sources
New to crypto? Read the crypto glossary, browse frequent questions, read our story, or explore the story archive.